Condition: Solid Tumours · Sponsor: Bristol-Myers Squibb
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0033 | Irvine, California, United States | Not Yet Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center | Orange, California, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Sanford Cancer Center | Sioux Falls, South Dakota, United States | Recruiting |
| START - Dallas Fort Worth | Fort Worth, Texas, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| START Mountain Region | West Valley City, Utah, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
| Herlev and Gentofte Hospital | Copenhagen, Capital Region, Denmark | Recruiting |
| Odense Universitetshospital | Odense, Region Syddanmark, Denmark | Recruiting |
| Copenhagen University Hospital Rigshospitalet | Copenhagen, Denmark | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07160725